Deuruxolitinib yields hair growth, satisfaction in patients with alopecia areata
Click Here to Manage Email Alerts
Key takeaways:
- A higher proportion of patients who received deuruxolitinib achieved the primary endpoint.
- Satisfaction was reported by 42.1% and 53% in the deuruxolitinib groups vs. 4.7% in the placebo group.
Patients with alopecia areata who were treated with deuruxolitinib experienced significant hair regrowth and reported satisfaction, according to a study.
“The clinical implications of deuruxolitinib are that we have a third medicine for this not uncommon disease,” Brett King, MD, PhD, associate professor of dermatology at Yale University School of Medicine and a member of Healio Dermatology’s Peer Perspective Board, told Healio. “This is important because failure of one JAK inhibitor does not mean that a patient will not succeed with another one.”
As Healio previously reported, Leqselvi (deuruxolitinib, Sun Pharma) 8 mg tablets, a twice-daily, oral, selective Janus kinase (JAK) 1 and 2 inhibitor, was recently approved by the FDA as the third systemic medication for severe alopecia areata.
The approval was supported by results from two multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trials, THRIVE-AA1 and THRIVE-AA2, and two open-label long-term extension trials.
Results from THRIVE-AA1 were recently published in the Journal of the American Academy of Dermatology, with the efficacy and safety of deuruxolitinib evaluated in patients aged 18 to 65 years with 50% or more hair loss from alopecia areata.
Each patient was randomly assigned to receive deuruxolitinib 8 mg twice daily (n = 351), deuruxolitinib 12 mg twice daily (n = 215) or placebo (n = 140) for 24 weeks.
A significantly higher proportion of patients in the deuruxolitinib groups achieved the primary endpoint of Severity of Alopecia Tool score of 20 or less compared with placebo (29.6% for 8 mg and 41.5% for 12 mg vs. 0.8% for placebo).
Satisfaction of hair patient-reported outcome was 42.1% and 53% in the deuruxolitinib 8 mg and 12 mg groups, respectively, vs. 4.7% in the placebo group.
Treatment-emergent adverse events were consistent with other oral JAK inhibitors and reported by 65.1% and 63.7% of patients in the deuruxolitinib 8 mg and 12 mg groups, respectively, and 55.7% in the placebo group. Two serious treatment-emergent adverse events related to the study drug occurred in one patient who received deuruxolitinib 8 mg. No deaths were reported.
“Having deuruxolitinib in our toolbox means that more patients with severe alopecia areata will be successfully treated,” King said.
Collapse
Read more about
Click Here to Manage Email Alerts